Onco3r’s SIK3 Inhibitor Completes First Phase 1 Cohort
Onco3R Therapeutics has completed the first multiple-ascending-dose cohort and four single-ascending-dose cohorts in a Phase 1 study of O3R-5671,...
RenovoRx CEO to Present at Best Ideas Investment Conference
RenovoRx will present at the iAccess Alpha Best Ideas Winter Investment Conference on December 9, spotlighting early commercial traction...
Plus Therapeutics Presents RESPECT Phase 1 Metastases Data
Plus Therapeutics will present Phase 1 dose-escalation results of rhenium-186 obisbemeda (ReYobiq), an injectable radiotherapy for leptomeningeal metastases, in...
Kala Bio Enters $6M Securities Purchase Agreement with Lazar
Kala Bio has secured a $6 million financing via non-voting convertible preferred stock from private investor David E. Lazar,...
CEO’s Spotlight on MediciNova’s Profitable Growth Path
MediciNova has completed enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of MN-001 (tipelukast) in patients with hypertriglyceridemia...
Empaveli Phase 3 VALIANT Results Published for C3G, IC-MPGN
Apellis’ pegcetacoplan has crossed a credibility threshold in rare nephrology: Phase 3 VALIANT results for C3 glomerulopathy and primary...
Lamy Completes Acquisition of Cancer Innovator Exousia AI
LAMY, soon to be rebranded as Exousia Bio (OTCPINK: LMMY), has completed an all‑stock acquisition of Exousia AI, issuing...
Lamy’s Strategic Acquisition of Exousia AI in Cancer Tech
Lamy, set to rebrand as Exousia Bio, has acquired 100% of Exousia AI in an all‑stock deal, issuing 62,223,000...
Novabridge Presents Ragistomig Expanded Phase 1 Data
NovaBridge Biosciences will present new data from its expanded phase 1 study of ragistomig (ABL503), a PD-L1 × 4-1BB...
TScan Virtual Event: Alloha™ Phase 1 Updates & Opportunities
TScan Therapeutics will host a virtual KOL event on December 8 to review updated two-year relapse data from its...